Srivastava, M., Murriel, C., Yun, R., Mayes, E., Jie, H., Axelrod, F., . . . Inkyung, P. A. (2015). Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. J Immunother Cancer.
Citação norma ChicagoSrivastava, Minu, et al. "Co-targeting of Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF) With Programmed Death 1 (PD1) Blockade Inhibits Tumor Growth and Facilitates Anti-tumor Immune Responses." J Immunother Cancer 2015.
Citação norma MLASrivastava, Minu, et al. "Co-targeting of Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF) With Programmed Death 1 (PD1) Blockade Inhibits Tumor Growth and Facilitates Anti-tumor Immune Responses." J Immunother Cancer 2015.